{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000821","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.163633+00:00","generated_at":"2026-06-07T04:35:40.758018+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortress Biotech closes registered direct offering of 3.3M units at $3.33 for $11M gross proceeds","bullets":["Offered 3,303,305 units at $3.33 each, each consisting of one share of common stock and one warrant.","Warrants have exercise price of $3.21 per share, immediately exercisable, expiring five years from issuance.","Gross proceeds approximately $11.0 million before placement agent fees and expenses.","Net proceeds to be used for operations, including R&D, clinical trials, acquisitions, and working capital.","Roth Capital Partners acted as exclusive placement agent with a 7% commission; offering closed on January 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000821","json":"https://secwatch.observer/filing/0001104659-24-000821.json","markdown":"https://secwatch.observer/filing/0001104659-24-000821.md","text":"https://secwatch.observer/filing/0001104659-24-000821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/tm241522d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:35:40.758018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a66edbc07f8298fb1571bc68a1c8dba7ba81ab4","claim":"Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers valued at approximately $11.0 million (effective 2023-11-10).","evidence_excerpt":"a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers"},{"label":"Value","value":"approximately $11.0 million"},{"label":"Effective","value":"2023-11-10"}],"fact_type":"material_agreement"},{"claim_id":"ddd8593c08e3af811528502dc73532ead49fc72d","claim":"Fortress Biotech, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2023-12-29).","evidence_excerpt":"a Placement Agency Agreement, dated as of December 29, 2023, between the Company and Roth (the “ Placement Agency Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Effective","value":"2023-12-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}